Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models |
| |
| Authors: | Idoia Gamez Robert P. Ryan Lakesha D. Reid Sheri M. Routt Beth A. Hollister |
| |
| Affiliation: | (1) Celtic Pharmaceutical Development Services America, Inc, 663 Fifth Ave, 7th Floor, New York, 10022, NY, USA;(2) Piedmont Research Center, Morrisville, NC, USA |
| |
| Abstract: | Purpose Corticorelin acetate (CrA) is a synthetic form of corticotropin-releasing factor undergoing clinical trials in the treatment of peritumoral brain edema (PBE). We sought to investigate preclinically its potential as an antitumor agent against human solid tumors and to assess its ability to enhance the therapeutic activity of bevacizumab (BEV) in these same models. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
